SPERA PHARMA (SPERA) was spun out from Takeda Pharmaceuticals and became a wholly owned subsidiary of Bushu Pharmaceuticals on July 1, 2017 in Osaka, Japan. On March 2, 2020, Iwaki & Co., Ltd acquired SPERA from Bushu. The IWAKI Group transitioned to a holding company structure under the new name “Astena Group” on June 1, 2021.
SPERA has about 250 employees including researchers and technical specialists in the areas of process chemistry, formulation, and analysis, whose prior work with Takeda gave them broad exposure to all aspects of pharmaceutical R&D, manufacturing, and life cycle management across myriad pharmaceutical products and therapeutic areas. They are engaged in contract R&D and manufacturing of pharmaceuticals for the pharmaceutical and biotech industry.
SPERA provides a wide offering of services as a CDMO to meet its customers’ needs across the CMC spectrum, including API and Drug Product process development and cGMP manufacturing, analytical method development, technology transfer, and regulatory filings. SPERA works with its clients on pharmaceutical technology as well as R&D strategy from early stages of drug development through to new drug application and launch. With the acquisition of Jitsubo Co., Ltd in April of 2021, SPERA PHARMA can now also offer Jitsubo’s unique liquid phase peptide manufacturing technology, Molecular Hiving™, to its clients.
SPERA’s CMC capabilities therapeutic area agnostic; however, most the company’s current clients are focused on oncology, immuno-oncology, CNS, immunology, and rare diseases. The company believes that their expertise in these areas enables them to deliver molecules more rapidly to their partners. SPERA intends to continually expand its efforts into other therapeutic areas with high unmet needs.
Company Details
- Employees
- 15
- Founded
- -
- Address
- 17-85 Jusohonmachi 2-Chome, Yodogawa-Ku, Osaka 532-0024, Japan, Osaka,japan
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- CDMO, CMC, Drug Product, API, Analytical Development, Sterile Injectables, Solid Dosage Forms, Process Development, Scale-up, GMP Manufacturing, Oncology, High Potency, HAPI, Peptides, Small Molecules.
- HQ
- Osaka
Spera Pharma, Inc. Questions
Spera Pharma, Inc.'s website is https://www.spera-pharma.co.jp/en/
Spera Pharma, Inc.'s LinkedIn profile is https://jp.linkedin.com/company/spera-pharma
Spera Pharma, Inc. has
15 employees.
View email and phone details for 15
employees at Spera Pharma, Inc..
Spera Pharma, Inc.'s industry is
Pharmaceutical Manufacturing
Spera Pharma, Inc.'s top competitors are
Teva Pharmaceuticals,
Kets Consultancy Services,
Spera Nexus,inc,
Yaohai Bio-Pharmaceutical Co., Ltd.,
Essen Biotech,
Rigaku,
Id Biotech,
Archimed,
Adragos Pharma,
Exalpha Biologicals, Inc..
Spera Pharma, Inc.'s categories are Pharmaceutical Manufacturing
Spera Pharma, Inc.'s founding year is 2017
